This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): donepezil HCL, E2020
Description: BioMedTracker has separate drug profiles for the SR and original formulations of Aricept. Please also see Aricept SR.
Aricept (donepezil hydrochloride) is a reversible inhibitor of the enzyme acetylcholinesterase, with less affinity for butyrylcholinesterase. Inhibition of cholinesterases, which break down acetylcholine, leads to increased levels of acetylcholine in the brain, helping to boost cognition in Alzheimer's disease, where acetylcholine containing nerves are reduced.
As of 2014, revenues are no longer reported for Aricept. As such, BioMedTracker no longer forecasts revenues.
In November 1994, Eisai and Pfizer announced the formation of a strategic alliance for the promotion of Aricept and development of new treatments for Alzheimer's disease and other cognitive disorders. Aricept is the lead compound in this alliance and will be co-promoted by Eisai Inc. and Pfizer sales forces in the U.S.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth. Eisai has the right to terminate the Strategic Alliance and Development Agreement with Pfizer with respect to Aricept upon consummation of Pfizer's acquisition of Wyeth.
In September 2009, Pfizer announced that its agreement with Eisai will continue without interruption. Under this redefined alliance, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe,...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Pink Sheet Appeals and Arbitration
Additional information available to subscribers only: